untitled design

AstraZeneca admits 'It wasn't our job to deal with coronavirus vaccines' – The goal in the 'post-Covid era'

Pharmaceutical company AstraZeneca, following the global withdrawal of its Covid-19 vaccine, plans to increase its total revenue to $80 billion by 2030, a 75% increase from $45.8 billion in 2023 “We believe this goal is achievable because of the breadth and scale of our portfolio,” AstraZeneca Chief Financial Officer (CFO) Aradhana Sarin said on “CNBC” on Tuesday. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and is expected to launch an additional 20 drugs over the next six years. “Many of these have the potential to become $5 billion drugs,” Sarin noted. AstraZeneca's plans include developing drugs to treat at least half of all possible cancers and developing alternatives to classic treatments such as chemotherapy and radiation. “To replace the entire market will take time, but we believe we have it today […]
Source: News Beast

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular